Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: 2 - You Need To See This

Eli Lilly shares bought on Trump’s behalf as his policies benefited drug firm

Filings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies

The Guardian - US

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Barchart

Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

MarketBeat

Do Wall Street Analysts Like Eli Lilly Stock?

While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

Evening Standard

Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

MarketBeat

Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s.

Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart.

Barchart

GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy?

Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge.

Barchart

Should You Buy the Dip in Eli Lilly Stock Today?

Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.

Barchart

Eli Lilly and Co Reportedly Close to $2 Billion Acquisition of Kelonia Therapeutics

Eli Lilly is reportedly nearing a $2 billion deal to acquire Kelonia Therapeutics, aiming to expand its cancer treatment portfolio with next-generation therapies.

International Business Times

Indiana, Eli Lilly to partner to bring nuclear power to the state

Nuclear is seen as key to AI energy needs, but it's years away from large-scale viability.

Axios

UAE introduces first-ever weight loss pill Foundayo, here’s how much it may cost and where to get it

The UAE has approved Foundayo (orforglipron), Eli Lilly's once-daily oral obesity pill, becoming one of the first countries globally to offer a needle-free alternative. This GLP-1 receptor agonist mimics natural hormones to regulate appetite and blood sugar, aiding weight loss and improving metabolic health. Available by prescription from May 2026,…

The Times of India

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be linked to liver, heart and gastrointestinal problems

Barchart

The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

The Independent UK

Trump sets 100% tariffs on prescription drugs from companies that have not reached a deal with him to lower prices

The tariffs were announced on the anniversary of Trump’s ‘Liberation Day,’ which saw U.S. trading partners hit with sweeping levies

Barchart

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience

Eli Lilly is securing its future by investing in AI drug discovery and expanding its pipeline into the multi-billion-dollar neuroscience market.

The Independent UK

Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable

IN FULL

Barchart

Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

The Guardian - US

US approves new oral weight-loss pill developed by Eli Lilly

Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy

The Independent UK

Foundayo: All you need to know about the newly approved weight-loss pill

The FDA authorized Eli Lilly's drug as part of a new program aimed at cutting drug approval times

Barchart

Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

Euronews

Eli Lilly invests in AI-designed drugs in new deal with Insilico Medicine worth up to €2.39bn

Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.